SIOP 2020 - 52nd Annual Congress of the International Society of Paediatric Oncology (Virtual Meeting)
Oct 14 - Oct 17, 2020 | OttawaCanada
LARVOL is not affiliated with 52nd Annual Congress of the International Society of Paediatric Oncology (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 10 abstracts linked to Trials
[VIRTUAL] HIGH-DOSE NAXITAMAB (HUMANIZED-3F8) PLUS STEPPED-UP DOSING OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) FOR RESISTANT OSTEOMEDULLARY NEUROBLASTOMA: MAJOR RESPONSES AND OUTPATIENT TREATMENT IN A PHASE II TRIAL
[VIRTUAL] NAXITAMAB-BASED CHEMOIMMUNOTHERAPY FOR RESISTANT HIGH-RISK NEUROBLASTOMA: PRELIMINARY RESULTS OF HITS TREATMENT.
[VIRTUAL] FAVORABLE TOXICITY PROFILE OF BIVALENT GD2/GD3 NEUROBLASTOMA VACCINE
[VIRTUAL] VALUE OF HIGH DOSE CHEMOTHERAPY WITH TREOSULFAN AND MELPHALAN IN PATIENTS WITH DISSEMINATED EWING SARCOMA. REPORT FROM THE INTERNATIONAL EWING 2008R3 TRIAL.
[VIRTUAL] VALUE OF ZOLENDRONIC ACID MAINTENANCE THERAPY IN PATIENTS WITH STANDARD RISK LOCALIZED EWING SARCOMA. REPORT FROM THE INTERNATIONAL EWING 2008 TRIAL.
[VIRTUAL] INTERNATIONAL, MULTICENTER PHASE II TRIAL WITH HUMANIZED ANTI-GD2 MONOCLONAL ANTIBODY NAXITAMAB FOR TREATMENT OF REFRACTORY/RELAPSED HIGH-RISK NEUROBLASTOMA: EFFICACY AND SAFETY DATA
[VIRTUAL] LAROTRECTINIB DEMONSTRATES DURABLE EFFICACY AND SAFETY IN AN EXPANDED DATASET OF PEDIATRIC PATIENTS WITH TRK FUSION CANCER
[VIRTUAL] UPDATED ENTRECTINIB DATA FROM A PHASE 1/2 TRIAL IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
[VIRTUAL] SAFETY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF COBIMETINIB IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY/RELAPSED SOLID TUMOURS: IMATRIX-COBI, A PHASE I/II STUDY
[VIRTUAL] PHASE 1 STUDY OF TAZEMETOSTAT, AN ENHANCER OF ZESTE HOMOLOG-2 (EZH2) INHIBITOR, IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY INTEGRASE INTERACTOR 1 (INI1)-NEGATIVE TUMORS